The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy
Abstract Background Anti-HER2 targeted therapy has significantly reduced the recurrence and death of HER2-overexpressing breast cancer patients, but might lead to cardiotoxicity. Some patients with normal myocardial function may suffer from subclinical myocardial dysfunction after anti-HER2 targeted...
Saved in:
| Main Authors: | Feng Zhang, Siyuan Wang, Chao Yu, Wenying Jin, Dan He, Xiaoxiao Hu, Shu Wang, Tiangang Zhu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13377-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation therapy
by: Jing Yang, et al.
Published: (2025-02-01) -
Cardiotoxicity of breast cancer drug treatments
by: Maria Haque, et al.
Published: (2025-05-01) -
Assessment of myocardial deformation by CMR tissue tracking reveals left ventricular subclinical myocardial dysfunction in patients with gynecologic cancer undergoing chemotherapy
by: Kai Tao, et al.
Published: (2025-02-01) -
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-04-01) -
Polyethyleneimine-polyethylene glycol copolymer targeted by anti-HER2 nanobody for specific delivery of transcriptionally targeted tBid containing construct
by: Batoul Saqafi, et al.
Published: (2019-12-01)